These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 25827441)

  • 1. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16-week, randomized, placebo-controlled trial.
    Ross S; Thamer C; Cescutti J; Meinicke T; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2015 Jul; 17(7):699-702. PubMed ID: 25827441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Initial Combination of Empagliflozin and Metformin in Patients With Type 2 Diabetes.
    Hadjadj S; Rosenstock J; Meinicke T; Woerle HJ; Broedl UC
    Diabetes Care; 2016 Oct; 39(10):1718-28. PubMed ID: 27493136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    Ridderstråle M; Andersen KR; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Lancet Diabetes Endocrinol; 2014 Sep; 2(9):691-700. PubMed ID: 24948511
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
    Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice-daily dapagliflozin co-administered with metformin in type 2 diabetes: a 16-week randomized, placebo-controlled clinical trial.
    Schumm-Draeger PM; Burgess L; Korányi L; Hruba V; Hamer-Maansson JE; de Bruin TW
    Diabetes Obes Metab; 2015 Jan; 17(1):42-51. PubMed ID: 25200570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
    Haering HU; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
    Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
    Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
    Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
    Ferrannini E; Seman L; Seewaldt-Becker E; Hantel S; Pinnetti S; Woerle HJ
    Diabetes Obes Metab; 2013 Aug; 15(8):721-8. PubMed ID: 23398530
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
    Rodbard HW; Rosenstock J; Canani LH; Deerochanawong C; Gumprecht J; Lindberg SØ; Lingvay I; Søndergaard AL; Treppendahl MB; Montanya E;
    Diabetes Care; 2019 Dec; 42(12):2272-2281. PubMed ID: 31530666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment with empagliflozin as add-on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus.
    Araki E; Tanizawa Y; Tanaka Y; Taniguchi A; Koiwai K; Kim G; Salsali A; Woerle HJ; Broedl UC
    Diabetes Obes Metab; 2015 Jul; 17(7):665-74. PubMed ID: 25772548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis.
    Lingvay I; Capehorn MS; Catarig AM; Johansen P; Lawson J; Sandberg A; Shaw R; Paine A
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4593-604. PubMed ID: 32827435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin compared with glimepiride in metformin-treated patients with type 2 diabetes: 208-week data from a masked randomized controlled trial.
    Ridderstråle M; Rosenstock J; Andersen KR; Woerle HJ; Salsali A;
    Diabetes Obes Metab; 2018 Dec; 20(12):2768-2777. PubMed ID: 29961998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of empagliflozin and linagliptin as second-line therapy in subjects with type 2 diabetes inadequately controlled on metformin.
    DeFronzo RA; Lewin A; Patel S; Liu D; Kaste R; Woerle HJ; Broedl UC
    Diabetes Care; 2015 Mar; 38(3):384-93. PubMed ID: 25583754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin as add-on to linagliptin in a fixed-dose combination in Japanese patients with type 2 diabetes: Glycaemic efficacy and safety profile in a 52-week, randomized, placebo-controlled trial.
    Kawamori R; Haneda M; Suzaki K; Cheng G; Shiki K; Miyamoto Y; Solimando F; Lee C; Lee J; George J
    Diabetes Obes Metab; 2018 Sep; 20(9):2200-2209. PubMed ID: 29766636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78-week randomized, double-blind, placebo-controlled trial.
    Rosenstock J; Jelaska A; Zeller C; Kim G; Broedl UC; Woerle HJ;
    Diabetes Obes Metab; 2015 Oct; 17(10):936-48. PubMed ID: 26040302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
    Häring HU; Merker L; Seewaldt-Becker E; Weimer M; Meinicke T; Broedl UC; Woerle HJ;
    Diabetes Care; 2014 Jun; 37(6):1650-9. PubMed ID: 24722494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes.
    Ferrannini E; Berk A; Hantel S; Pinnetti S; Hach T; Woerle HJ; Broedl UC
    Diabetes Care; 2013 Dec; 36(12):4015-21. PubMed ID: 24186878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
    Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
    Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
    Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial.
    Søfteland E; Meier JJ; Vangen B; Toorawa R; Maldonado-Lutomirsky M; Broedl UC
    Diabetes Care; 2017 Feb; 40(2):201-209. PubMed ID: 27913576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.